Incannex Healthcare (IXHL) Metrics: History & Chart

Incannex Healthcare Limited(IXHL)

Biotechnology · Sydney, NSW

$3.15-0.06 (-1.81%)

Delayed quote: Oct 6, 2026, 1:04 PM EDT

About Incannex Healthcare Limited

Incannex Healthcare Limited is an Australian company dedicated to the research, development, and commercialization of medicinal cannabinoid products. The firm offers pharmaceutical-grade cannabinoid compounds under its proprietary Incannex brand. Its product pipeline includes several key assets: IHL-42X: This compound is currently undergoing Phase II clinical evaluation for the treatment of obstructive sleep apnea (OSA). Incannex partners with The Alfred Hospital and Novotech on this specific clinical program. IHL-216A: Designed to address traumatic brain injury (TBI). Furthermore, the Monash Trauma Group, part of Monash University's Department of Neuroscience, is conducting a study on IHL-216A's protective effects against sports-related concussions. IHL-675A: A unique formulation combining hydroxychloroquine and cannabidiol, developed for both the prevention and management of a range of inflammatory conditions. These include acute respiratory distress syndrome (ARDS), chronic obstructive pulmonary disease (COPD), asthma, bronchitis, rheumatoid arthritis, and inflammatory bowel diseases. Originally established in 2001 as Impression Healthcare Limited, the company officially changed its name to Incannex Healthcare Limited in June 2020. Incannex maintains its corporate headquarters in Sydney, Australia.

Sydney, NSW

12 employees

www.incannex.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Joel Bradley Latham

View full financials

Third-Party DCF Estimate (FMP)	$4.04
Price Gap vs Third-Party Estimate	+25.94%

7D Total Return	+1.91%
30D Total Return	-1.23%
YTD Total Return	-70.11%
1Y Total Return	-77.79%
3Y Total Return	-97.55%
5Y Total Return	N/A
10Y Total Return	N/A
15Y Total Return	N/A
20Y Total Return	N/A

2026	-70.11%
2025	-83.11%
2024	-54.31%
2023	-58.57%
2022	N/A
2021	N/A

CAGR TTM	-77.63%
CAGR 3Y	-70.93%
CAGR 5Y	N/A
CAGR 10Y	N/A
CAGR 15Y	N/A
CAGR 20Y	N/A

PE Ratio	N/A
PE Ratio Avg TTM	N/A
PE Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

All Metrics

IXHL Valuation Metrics

IXHL Stock Price Metrics

IXHL Dividend Metrics

IXHL Growth Rate Metrics

IXHL Discounted Cash Flow Metrics

IXHL Returns By Period

IXHL Yearly Returns

IXHL Average Annual Returns By Period (CAGR)

IXHL Revenue Metrics

IXHL PE Ratio Metrics

IXHL PS Ratio Metrics

IXHL PB Ratio Metrics

IXHL Price to Free Cash Flow Ratio Metrics

IXHL Debt to Equity Ratio Metrics

IXHL PEG Ratio Metrics

IXHL FCF Yield

IXHL Earnings Yield

IXHL EBITDA Yield

IXHL OCF Yield

IXHL EV/EBIT Ratio Metrics

IXHL EV/EBITDA Ratio Metrics

IXHL EV/Assets Ratio Metrics

IXHL EV/Sales Ratio Metrics

IXHL Current Ratio Metrics

IXHL Quick Ratio Metrics

IXHL ROIC Metrics

IXHL Return on Assets Metrics

IXHL Return on Equity Metrics

IXHL Net Profit Margin Metrics

IXHL Gross Profit Margin Metrics

IXHL Tax Rate Metrics

PS Ratio	N/A
PS Ratio Avg TTM	N/A
PS Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

PB Ratio	0.59
PB Ratio Avg TTM	3.45
PB Ratio Avg 3Y	3.88
Current VS TTM Avg	-82.91%
Current VS 3Y Avg	-84.78%
Current VS 5Y Avg	-93.99%

PFCF Ratio	N/A
PFCF Ratio Avg TTM	N/A
PFCF Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Debt/Equity Ratio	0.00
Debt/Equity Ratio Avg TTM	0.01
Debt/Equity Ratio Avg 3Y	0.62
Current VS TTM Avg	-81.35%
Current VS 3Y Avg	-99.77%
Current VS 5Y Avg	-99.64%

PEG Ratio	N/A
PEG Ratio Avg TTM	N/A
PEG Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

FCF Yield	N/A
FCF Yield Avg TTM	N/A
FCF Yield Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Earnings Yield	N/A
Earnings Yield Avg TTM	N/A
Earnings Yield Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

EBITDA Yield	N/A
EBITDA Yield Avg TTM	N/A
EBITDA Yield Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

OCF Yield	N/A
OCF Yield Avg TTM	N/A
OCF Yield Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Ev/Ebit Ratio	N/A
Ev/Ebit Ratio Avg TTM	N/A
Ev/Ebit Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Ev/Ebitda Ratio	N/A
Ev/Ebitda Ratio Avg TTM	N/A
Ev/Ebitda Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Ev/Assets Ratio	0.01
Ev/Assets Ratio Avg TTM	4.90
Ev/Assets Ratio Avg 3Y	13.64
Current VS TTM Avg	-99.80%
Current VS 3Y Avg	-99.93%
Current VS 5Y Avg	-99.93%

Ev/Sales Ratio	N/A
Ev/Sales Ratio Avg TTM	N/A
Ev/Sales Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Current Ratio	48.81
Current Ratio Avg TTM	33.31
Current Ratio Avg 3Y	17.19
Current VS TTM Avg	+46.52%
Current VS 3Y Avg	+183.93%
Current VS 5Y Avg	+137.88%

Quick Ratio	48.81
Quick Ratio Avg TTM	33.31
Quick Ratio Avg 3Y	17.19
Current VS TTM Avg	+46.52%
Current VS 3Y Avg	+183.93%
Current VS 5Y Avg	+137.88%

ROIC	(32.18%)
ROIC Avg 3Y	(133.41%)
ROIC Avg 5Y	(116.42%)
Current VS 3Y Avg	+75.88%
Current VS 5Y Avg	+72.36%
Current VS 10Y Avg	+97.42%

ROA	(26.45%)
ROA Avg TTM	(66.73%)
ROA Avg 3Y	(18.97%)
Current VS TTM Avg	+60.36%
Current VS 3Y Avg	-39.40%
Current VS 5Y Avg	-33.98%

ROE	(28.65%)
ROE Avg TTM	N/A
ROE Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Net Profit Margin	0.00%
Net Profit Margin Avg TTM	(17799.53%)
Net Profit Margin Avg 3Y	(8674.70%)
Current VS TTM Avg	+100.00%
Current VS 3Y Avg	+100.00%
Current VS 5Y Avg	+100.00%

Gross Profit Margin	0.00%
Gross Pft Margin Avg TTM	(64.23%)
Gross Pft Margin Avg 3Y	(13.24%)
Current VS TTM Avg	+100.00%
Current VS 3Y Avg	+100.00%
Current VS 5Y Avg	-100.00%

Tax Rate	19.44%
Tax Rate Avg 3Y	5.72%
Tax Rate Avg 5Y	3.81%
Current VS 3Y Avg	+239.71%
Current VS 5Y Avg	+409.57%
Current VS 10Y Avg	+465.56%